Actively Recruiting

Phase 2
Age: 18Years - 50Years
All Genders
ID07533006

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY4005130 in Adults With Severe Alopecia Areata

Led by Eli Lilly and Company · Updated on 2026-06-04

60

Participants Needed

30

Research Sites

17 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating how well LY4005130 works for adults with severe alopecia areata, a condition causing significant hair loss. This Phase 2 study compares LY4005130 with a placebo to assess its effects, how well participants tolerate it, and possible side effects. Blood tests will be used to understand how the body processes the drug and how the drug affects the body. Participants will receive either LY4005130 or a placebo through an intravenous (IV) infusion into a vein in the arm. The study is randomized, double-blind, and placebo-controlled to ensure unbiased results. The treatment period and overall study duration last about 48 weeks, including screening time. During the study, participants will undergo regular assessments including the Severity of Alopecia Tool (SALT) to measure hair loss improvement. Researchers will also monitor drug levels in the blood and changes in gene expression from scalp biopsies. The primary outcome is the percentage of participants achieving a SALT score of 20 or less by week 24. Safety and tolerability will be closely observed throughout the study.

CONDITIONS

Brief Title

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

Who Can Participate

Age: 18Years - 50Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 50 years
  • Severe alopecia areata with 50% to 90% scalp hair loss measured by SALT score
  • Current episode lasting at least 6 months and no more than 4 years
  • No significant spontaneous hair regrowth for at least 6 months
  • Agree not to use any alopecia areata treatments during the study
Not Eligible

You will not qualify if you...

  • Having primarily diffuse type of alopecia areata
  • Experiencing other forms of alopecia
  • History or current unstable disease requiring frequent hospitalizations or systemic immunosuppressants
  • Previous use of oral JAK inhibitors
  • Major surgery within 8 weeks before screening or planned during the study
  • History or presence of serious cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, neuropsychiatric disorders, or other serious unstable illnesses

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 24 weeks

Participants receive LY4005130 or placebo administered intravenously as part of the study treatment.

Regular visits during treatment period to receive intravenous administration and assessments

Trial Site Locations

Total: 30 locations

1

Center For Dermatology Clinical Research, Inc.

Fremont, California, United States, 94538

Actively Recruiting

2

Northridge Clinical Trials

Northridge, California, United States, 91325

Actively Recruiting

3

Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway

Santa Clarita, California, United States, 91355

Not Yet Recruiting

4

Health Clinical Research, LLC

Cutler Bay, Florida, United States, 33189

Actively Recruiting

5

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115

Not Yet Recruiting

6

Revival Research Institute, LLC

Troy, Michigan, United States, 48084

Actively Recruiting

7

Stracskin

Portsmouth, New Hampshire, United States, 03801

Actively Recruiting

8

Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue

San Antonio, Texas, United States, 78235

Actively Recruiting

9

Jordan Valley Dermatology & Research Center

South Jordan, Utah, United States, 84095

Actively Recruiting

10

Kelowna Health and Memory Centre

Kelowna, Canada, V1Y 5A8

Not Yet Recruiting

11

Ryan Clinical Research Inc.

Newmarket, Canada, L3Y 5G8

Not Yet Recruiting

12

Dar Clinical Research - Ottawa - Hunt Club Road

Ottawa, Canada, K1V 1C1

Not Yet Recruiting

13

SIMa Recherche

Verdun, Canada, H4G 2L8

Not Yet Recruiting

14

Beijing Friendship Hospital Affiliate of Capital University

Beijing, China, 100050

Not Yet Recruiting

15

Huashan Hospital, Fudan University

Shanghai, China, 200040

Not Yet Recruiting

16

Shanghai Skin Disease Hospital

Shanghai, China, 200071

Not Yet Recruiting

17

Tianjin Medical University General Hospital

Tianjin, China, 300052

Not Yet Recruiting

18

Erasmus Medisch Centrum

Rotterdam, Netherlands, 3015 GD

Not Yet Recruiting

19

Centrum Badan Klinicznych PI-House sp. z o.o.

Gdansk, Poland, 80-546

Not Yet Recruiting

20

Diamond Clinic

Krakow, Poland, 31-559

Not Yet Recruiting

21

Dermedic Jacek Zdybski

Ostrowiec Świętokrzyski, Poland, 27-400

Not Yet Recruiting

22

Centrum Medyczne Ginemedica

Wroclaw, Poland, 50-414

Not Yet Recruiting

23

Chung-Ang University Hospital

Dongjak-gu, South Korea, 06973

Not Yet Recruiting

24

Inha University Hospital

Incheon, South Korea, 22332

Not Yet Recruiting

25

Jeonbuk National University Hospital

Jeonju, South Korea, 54907

Not Yet Recruiting

26

Seoul National University Hospital

Seoul, South Korea, 03080

Not Yet Recruiting

27

Kyung Hee University Hospital at Gangdong

Seoul, South Korea, 05278

Not Yet Recruiting

28

Royal London Hospital

London, United Kingdom, E1 1FR

Not Yet Recruiting

29

Chelsea and Westminster Hospital NHS Foundation Trust

London, United Kingdom, SW10 9NH

Not Yet Recruiting

30

Salford Royal Hospital

Salford, United Kingdom, M6 8HD

Not Yet Recruiting

Loading map...

Research Team

T

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

P

Physicians interested in becoming principal investigators please contact

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Multi-Country, Cross-sectional Study to Characterize Real Wo...

Non-Segmental Vitiligo (NSV)

Actively Recruiting

116 locations

A Phase 2, Randomized, Double-blind, Placebo-controlled Stud...

Alopecia Areata

Actively Recruiting

1 location

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study...

Alopecia Areata

Actively Recruiting

15 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here